These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32928644)

  • 21. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein.
    Obergasteiger J; Überbacher C; Pramstaller PP; Hicks AA; Corti C; Volta M
    Biochem Biophys Res Commun; 2017 Aug; 490(3):876-881. PubMed ID: 28647363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
    Cookson MR
    Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
    Devine MJ; Lewis PA
    FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.
    Sen S; West AB
    Antioxid Redox Signal; 2009 Sep; 11(9):2167-87. PubMed ID: 19271991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
    Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
    Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey.
    Kessler C; Atasu B; Hanagasi H; Simón-Sánchez J; Hauser AK; Pak M; Bilgic B; Erginel-Unaltuna N; Gurvit H; Gasser T; Lohmann E
    Parkinsonism Relat Disord; 2018 Mar; 48():34-39. PubMed ID: 29248340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.
    Andersen MA; Christensen KV; Badolo L; Smith GP; Jeggo R; Jensen PH; Andersen KJ; Sotty F
    Neurobiol Dis; 2018 Aug; 116():13-27. PubMed ID: 29680709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNCA but not DNM3 and GAK modifies age at onset of LRRK2-related Parkinson's disease in Chinese population.
    Yang ZH; Li YS; Shi MM; Yang J; Liu YT; Mao CY; Fan Y; Hu XC; Shi CH; Xu YM
    J Neurol; 2019 Jul; 266(7):1796-1800. PubMed ID: 31041581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LRRK2 pathobiology in Parkinson's disease - virtual inclusion.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2016 Oct; 139 Suppl 1():75-76. PubMed ID: 26899799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Kalia LV
    Parkinsonism Relat Disord; 2020 May; 74():78-79. PubMed ID: 31727562
    [No Abstract]   [Full Text] [Related]  

  • 36. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
    Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
    eNeuro; 2017; 4(2):. PubMed ID: 28321439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 activation in idiopathic Parkinson's disease.
    Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT
    Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Stroke Risk in Patients with Parkinson's Disease with LRRK2 Mutations.
    Macías-García D; Periñán MT; Muñoz-Delgado L; Jesús S; Jimenez-Jaraba MV; Buiza-Rueda D; Bonilla-Toribio M; Adarmes-Gómez A; Carrillo F; Gómez-Garre P; Mir P
    Mov Disord; 2022 Jan; 37(1):225-227. PubMed ID: 34859503
    [No Abstract]   [Full Text] [Related]  

  • 39. Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).
    Beylina A; Langston RG; Rosen D; Reed X; Cookson MR
    Stem Cell Res; 2021 May; 53():102354. PubMed ID: 34087985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.